HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.5%

Neg 0% Neu 88.5% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy and maintains $81 price target.